Comparison · NCT02927249-sae
Arm I (Aspirin) vs Arm II (Placebo): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm I (Aspirin) vs Arm II (Placebo): serious adverse events. Trial comparisons, record NCT02927249-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02927249-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0711 | 0.0587 | 0.0858 | wilson | |
| Risk in group 2 | 0.0643 | 0.0527 | 0.0783 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00676 | -0.0119 | 0.0255 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.11 | 0.84 | 1.45 | log | |
| Odds ratio, group 1 over group 2 | 1.11 | 0.829 | 1.49 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Arm I (Aspirin) than on Arm II (Placebo) | 148 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm I (Aspirin) | Patients receive aspirin PO QD for five years in the absence of disease progression or unacceptable toxicity. | 99 | 1,393 | EG000 |
| Group 2 | Arm II (Placebo) | Patients receive placebo PO QD for five years in the absence of disease progression or unacceptable toxicity. | 91 | 1,415 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 5 years
Source ClinicalTrials.gov
Trial
- Title
- Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
- NCT number
- NCT02927249
- Phases
- PHASE3
- Conditions
- Node Positive HER2 Negative Breast Cancer
- Interventions
- Placebo, Aspirin
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Results first posted
- 2023-03-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02927249?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02927249-sae